Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we?
Journal
Current opinion in otolaryngology & head and neck surgery
ISSN: 1531-6998
Titre abrégé: Curr Opin Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 9417024
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
The prevalence of thyroid nodules in the general population is high but only about 5% are malignant lesions. Cytology is usually appropriate to rule out malignancy in sonographically suspicious nodules but in many cases, reports are indeterminate. Molecular testing is a more recent approach to rule out malignancy and guide subsequent management. Although several different molecular testing approaches have proven useful in reducing unnecessary surgery, there are still several remaining issues, such as the possible occurrence of RAS mutations (which are difficult to interpret in clinical management) and the role of molecular analysis in specific histotypes, such as Hürthle cell carcinomas. Furthermore, conclusive evidence is lacking regarding the cost-effectiveness and appropriateness of surgical options following molecular tests. To be useful in clinical practice, molecular tests should be applied to appropriate candidates. In truly uncertain thyroid nodules in which diagnostic surgery may be considered, molecular testing may change the clinical approach and 'save' a number of thyroids.
Identifiants
pubmed: 33664196
doi: 10.1097/MOO.0000000000000698
pii: 00020840-202104000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-112Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Grani G, Sponziello M, Pecce V, et al. Contemporary thyroid nodule evaluation and management. J Clin Endocrinol Metab 2020; 105:2869–2883.
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017; 27:1341–1346.
Baloch Z, LiVolsi VA. The Bethesda System for Reporting Thyroid Cytology (TBSRTC): from look-backs to look-ahead. Diagn Cytopathol 2020; 48:862–866.
Stewart R, Leang YJ, Bhatt CR, et al. Quantifying the differences in surgical management of patients with definitive and indeterminate thyroid nodule cytology. Eur J Surg Oncol 2020; 46:252–257.
Cantisani V, David E, Grazhdani H, et al. Prospective evaluation of semiquantitative strain ratio and quantitative 2D ultrasound shear wave elastography (SWE) in association with TIRADS classification for thyroid nodule characterization. Ultraschall Med 2019; 40:495–503.
Trimboli P, Castellana M, Virili C, et al. Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. Radiol Med 2020; 125:406–415.
Allen L, Al Afif A, Rigby MH, et al. The role of repeat fine needle aspiration in managing indeterminate thyroid nodules. J Otolaryngol Head Neck Surg 2019; 48:16.
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol 2019; 5:204–212.
San Martin VT, Lawrence L, Bena J, et al. Real-world comparison of Afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2020; 105:dgz099doi: doi: 10.1210/clinem/dgz099.
doi: 10.1210/clinem/dgz099
Wei S, Veloski C, Sharda P, Ehya H. Performance of the Afirma Genomic Sequencing Classifier versus gene expression classifier: an institutional experience. Cancer Cytopathol 2019; 127:720–724.
Angell TE, Heller HT, Cibas ES, et al. Independent comparison of the Afirma Genomic Sequencing Classifier and gene expression classifier for cytologically indeterminate thyroid nodules. Thyroid 2019; 29:650–656.
Geng Y, Aguilar-Jakthong JS, Moatamed NA. Comparison of Afirma Gene Expression Classifier with gene sequencing classifier in indeterminate thyroid nodules: a single-institutional experience. Cytopathology 2020; doi: 10.1111/cyt.12920.
doi: 10.1111/cyt.12920
Vuong HG, Nguyen TPX, Hassell LA, Jung CK. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the gene expression classifier: a meta-analysis. Cancer Cytopathol 2020; doi: 10.1002/cncy.22332.
doi: 10.1002/cncy.22332
Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg 2018; 153:817–824.
Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol 2020; doi:10.1001/jamaoncol.2020.5935.
doi: 10.1001/jamaoncol.2020.5935
Celano M, Rosignolo F, Maggisano V, et al. MicroRNAs as biomarkers in thyroid carcinoma. Int J Genomics 2017; 2017:6496570.
Rosignolo F, Memeo L, Monzani F, et al. MicroRNA-based molecular classification of papillary thyroid carcinoma. Int J Oncol 2017; 50:1767–1777.
Lupo MA, Walts AE, Sistrunk JW, et al. Multiplatform molecular test performance in indeterminate thyroid nodules. Diagn Cytopathol 2020; 48:1254–1264.
Sistrunk JW, Shifrin A, Frager M, et al. Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules. J Am Soc Cytopathol 2020; 9:232–241.
Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 2018; 124:1682–1690.
González HE, Martínez JR, Vargas-Salas S, et al. A 10-gene classifier for indeterminate thyroid nodules: development and multicenter accuracy study. Thyroid 2017; 27:1058–1067.
Nikiforova MN, Lepe M, Tolino LA, et al. Thyroid cytology smear slides: an untapped resource for ThyroSeq testing. Cancer Cytopathol 2020; 129:33–42.
Verrienti A, Pecce V, Abballe L, et al. Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue. Endocrine 2020; 69:451–455.
Zhao H, Jing W, Li W, et al. Risk Stratification study of indeterminate thyroid nodules with a next-generation sequencing assay with residual ThinPrep® material. J Cancer 2020; 11:7276–7282.
Heymann JJ, Yoxtheimer LM, Park HJ, et al. Preanalytic variables in quality and quantity of nucleic acids extracted from FNA specimens of thyroid gland nodules collected in CytoLyt: cellularity and storage time. Cancer Cytopathol 2020; 128:656–672.
Perdana AB, Putri RI, Rachmawati R, et al. Clinical utility of BRAF, NRAS, and TERT promoter mutation in preoperative thyroid fine-needle aspiration biopsy: a diagnostic study from Dharmais Cancer Hospital. Asian Pac J Cancer Prev 2020; 21:3267–3277.
Bardet S, Goardon N, Lequesne J, et al. Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study. Endocrine 2020; doi: 10.1007/s12020-020-02411-4.
doi: 10.1007/s12020-020-02411-4
Sponziello M, Brunelli C, Verrienti A, et al. Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules. Endocrine 2020; 68:458–465.
Possieri C, Locantore P, Salis C, et al. Combined molecular and mathematical analysis of long noncoding RNAs expression in fine needle aspiration biopsies as novel tool for early diagnosis of thyroid cancer. Endocrine 2020; doi: 10.1007/s12020-020-02508-w.
doi: 10.1007/s12020-020-02508-w
Guan H, Toraldo G, Cerda SR, et al. Utilities of RAS mutations in preoperative fine needle biopsies for decision-making for thyroid nodule management: results from a single-center prospective cohort. Thyroid 2020; 30:536–547.
Nabhan F, Porter K, Lupo MA, et al. Heterogeneity in positive predictive value of RAS mutations in cytologically indeterminate thyroid nodules. Thyroid 2018; 28:729–738.
Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 2008; 130:736–744.
Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004; 28:1336–1340.
Ohori NP, Landau MS, Carty SE, et al. Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathol 2019; 127:161–168.
Hernandez-Prera JC, Valderrabano P, Creed JH, et al. Molecular determinants of thyroid nodules with indeterminate cytology and RAS mutations. Thyroid 2020; doi: 10.1089/thy.2019.0650.
doi: 10.1089/thy.2019.0650
Parajuli S, Jug R, Ahmadi S, Jiang XS. Hurthle cell predominance impacts results of Afirma Gene Expression Classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules. Diagn Cytopathol 2019; 47:1177–1183.
Endo M, Nabhan F, Angell TE, et al. Use of molecular diagnostic tests in thyroid nodules with Hürthle cell-dominant cytology. Thyroid 2020; 30:1390–1392.
Gilani SM, Ross JA, Prasad ML, et al. Molecular alterations in Hürthle cell neoplasms of thyroid: a fine needle aspiration cytology study with cytology-histology correlation. Cancer Cytopathol 2020; doi: 10.1002/cncy.22370.
doi: 10.1002/cncy.22370
Schatz-Siemers N, Brandler TC, Oweity T, et al. Hürthle cell lesions on thyroid fine needle aspiration cytology: molecular and histologic correlation. Diagn Cytopathol 2019; 47:977–985.
Hao Y, Duh QY, Kloos RT, et al. Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms. BMC Syst Biol 2019; 13: (Suppl): 27.
Lee M, Valero C, Morris LGT, Marti JL. Association of study methods and industry sponsorship with inconsistent performance of molecular assays for indeterminate thyroid nodules. JAMA Otolaryngol Head Neck Surg 2020; doi: 10.1001/jamaoto.2020.3252.
doi: 10.1001/jamaoto.2020.3252
Nicholson KJ, Roberts MS, McCoy KL, et al. Molecular testing versus diagnostic lobectomy in Bethesda III/IV thyroid nodules: a cost-effectiveness analysis. Thyroid 2019; 29:1237–1243.
Chen T, Gilfix BM, Rivera J, et al. The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the Canadian Public Healthcare Setting. Thyroid 2020; 30:1280–1287.
Wong CW, Schumm MA, Zhu CY, et al. Quality of life following molecular marker testing for indeterminate thyroid nodules. Endocr Pract 2020; 26:960–966.
Lamartina L, Grani G, Durante C, Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res 2018; 7:86.
Mitchell J, Yip L. Decision making in indeterminate thyroid nodules and the role of molecular testing. Surg Clin North Am 2019; 99:587–598.
Krasner JR, Alyouha N, Pusztaszeri M, et al. Molecular mutations as a possible factor for determining extent of thyroid surgery. J Otolaryngol Head Neck Surg 2019; 48:51.
Khan TM, Zeiger MA. Thyroid nodule molecular testing: is it ready for prime time? Front Endocrinol (Lausanne) 2020; 11:590128.
Noureldine SI, Olson MT, Agrawal N, et al. Effect of gene expression classifier molecular testing on the surgical decision-making process for patients with thyroid nodules. JAMA Otolaryngol Head Neck Surg 2015; 141:1082–1088.
Noureldine SI, Najafian A, Aragon Han P, et al. Evaluation of the effect of diagnostic molecular testing on the surgical decision-making process for patients with thyroid nodules. JAMA Otolaryngol Head Neck Surg 2016; 142:676–682.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2017; 317:1882–1887.
Lamartina L, Grani G, Durante C, et al. Screening for differentiated thyroid cancer in selected populations. Lancet Diabetes Endocrinol 2020; 8:81–88.
Grani G, Lamartina L, Ascoli V, et al. Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: toward the ‘right’ TIRADS. J Clin Endocrinol Metab 2019; 104:95–102.
Ramundo V, Sponziello M, Falcone R, et al. Low-risk papillary thyroid microcarcinoma: optimal management toward a more conservative approach. J Surg Oncol 2020; 121:958–963.
Wang MM, Beckett K, Douek M, et al. Diagnostic value of molecular testing in sonographically suspicious thyroid nodules. J Endocr Soc 2020; 4:bvaa081.